恒瑞医药：SHR7280片上市许可申请获受理

Core Viewpoint - Heng Rui Medicine (600276.SH) has received acceptance from the National Medical Products Administration (NMPA) for its drug application SHR7280 tablets, aimed at controlling ovarian stimulation in assisted reproductive technology [1] Group 1 - The drug SHR7280 is intended for use in patients undergoing controlled ovarian stimulation therapy [1] - The application is specifically for preventing early luteinizing hormone (LH) peaks [1]